Pulmonx (NASDAQ:LUNG – Get Free Report) and SS Innovations International (NASDAQ:SSII – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.
Valuation & Earnings
This table compares Pulmonx and SS Innovations International”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 0.93 | -$54.00 million | ($1.16) | -1.68 |
| SS Innovations International | $42.49 million | 11.18 | -$12.13 million | ($0.06) | -39.50 |
SS Innovations International has lower revenue, but higher earnings than Pulmonx. SS Innovations International is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Pulmonx has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, SS Innovations International has a beta of -1.79, meaning that its share price is 279% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Pulmonx and SS Innovations International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| SS Innovations International | 1 | 0 | 0 | 0 | 1.00 |
Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 293.16%. SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 195.36%. Given Pulmonx’s stronger consensus rating and higher probable upside, research analysts plainly believe Pulmonx is more favorable than SS Innovations International.
Profitability
This table compares Pulmonx and SS Innovations International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -55.03% | -96.66% | -38.32% |
| SS Innovations International | -23.73% | -26.77% | -15.01% |
Institutional and Insider Ownership
91.0% of Pulmonx shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Pulmonx beats SS Innovations International on 7 of the 13 factors compared between the two stocks.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
About SS Innovations International
AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
